Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis

Journal of Neuroscience

Volumn 31, Issue 23, 2011, Pages 8329-8341

  Ren, Zhihua ^a   Wang, Yan ^a   Tao, Duan ^a   Liebenson, David ^a   Liggett, Thomas ^a   Goswami, Rajendra ^a   Clarke, Robert ^b   Stefoski, Dusan ^a   Balabanov, Roumen ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1BETA CONVERTING ENZYME; PERTUSSIS TOXIN; STAT1 PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DEMYELINATION; ENZYME ACTIVITY; FEMALE; IMMUNE RESPONSE; MOUSE; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; DEMYELINATING DISEASES; ELECTROPHORESIS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERFERON REGULATORY FACTOR-1; MICE; MICE, TRANSGENIC; OLIGODENDROGLIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79958279017     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1028-11.2011     Document Type: Article

References (50)

1. Agresti C, Bernardo A, Del Russo N, Marziali G, Battistini A, Aloisi F, Levi G, Coccia EM (1998) Synergistic stimulation of MHC class I and IRF-1 gene expression by IFN-gamma and TNF-alpha in oligodendrocytes. Eur J Neurosci 10:2975-2983.
2. Aguirre A, Dupree JL, Mangin JM, Gallo V (2007) A functional role for EGFR signaling in myelination and remyelination. Nat Neurosci 10: 990-1002.
3. Balabanov R, Strand K, Kemper A, Lee JY, Popko B (2006) Suppressor of cytokine signaling 1 expression protects oligodendrocytes from the deleterious effects of interferon-gamma. J Neurosci 26:5143-5152.
4. Balabanov R, Strand K, Goswami R, McMahon E, Begolka W, Miller SD, Popko B (2007) Interferon-gamma-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J Neurosci 27:2013-2024.
5. Barnett MH, Prineas JW (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55:458-468.
6. Bergsbaken T, Fink SL, Cookson BT (2009) Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 7:99-109.
7. Bouker K, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A, Wang A, Clarke R (2005) Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis 26:1527-1535.
8. Brady ST, Witt AS, Kirkpatrick LL, de Waegh SM, Readhead C, Tu PH, Lee VM (1999) Formation of compact myelin is required for maturation of the axonal cytoskeleton. J Neurosci 19:7278-7288.
9. Buch T, Uthoff-Hachenberg C, Waisman A (2003) Protection from autoimmune brain inflammation in mice lacking IFN-regulatory factor-1 is associated with Th2-type cytokines. Int Immunol 15:855-859.
10. Butzkueven H, Zhang JG, Soilu-Hanninen M, Hochrein H, Chionh F, Shipham KA, Emery B, Turnley AM, Petratos S, Ernst M, Bartlett PF, Kilpatrick TJ (2002) LIF receptor signaling limits immune mediated de-myelination by enhancing oligodendrocyte survival. Nat Med 8:613-619.
11. Corbin JG, Kelly D, Rath EM, Baerwald KD, Suzuki K, Popko B (1996) Targeted CNS expression of interferon-gamma in transgenic mice leads to hypomyelination, reactive gliosis, and abnormal cerebellar development. Mol Cell Neurosci 7:354-370.
12. Edgar JM, Garbern J (2004) The myelinated axon is dependent on the my-elinating cell for support and maintenance: molecules involved. J Neuro-sci Res 76:593-598.
13. Ercolini AM, Miller SD (2006) Mechanisms of immunopathology in mu-rine models of central nervous system demyelinating disease. J Immunol 176:3293-3298.
14. Fink SL, Cookson BT (2005) Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun 73:1907-1916.
15. Fortunato G, Calcagno G, Bresciamorra V, Salvatore E, Filla A, Capone S, Liguori R, Borelli S, Gentile I, Borrelli F, Borgia G, Sacchetti L (2008) Multiple sclerosis and hepatitis Cvirus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cy-tokine Res 28:141-152.
16. Furlan R, Martino G, Galbiati F, Poliani PL, Smiroldo S, Bergami A, Desina G, Comi G, Flavell R, Su MS, Adorini L (1999) Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol 163:2403-2409.
17. Gravel M, Di Polo A, Valera PB, Braun PE (1998) Four-kilobase sequence of the mouse CNP gene directs spatial and temporal expression of lacZ in transgenic mice. J Neurosci Res 53:393-404.
18. Heine S, Ebnet J, Maysami S, Stangel M (2006) Effects of interferon-beta on oligodendroglial cells. J Neuroimmunol 177:173-180.
19. Hisahara S, Araki T, Sugiyama F, Yagami K, Suzuki M, Abe K, Yamamura K, Miyazaki J, Momoi T, Saruta T, Bernard CC, Okano H, Miura M (2000) Targeted expression of baculovirus p35 caspase inhibitor in oligodendro-cytes protects mice against autoimmune-mediated demyelination. EMBO J 19:341-348.
20. Hisahara S, Okano H, Miura M (2003) Caspase-mediated oligodendrocyte cell death in the pathogenesis of autoimmune demyelination. Neurosci Res 46:387-397.
21. Hoftberger R, Aboul-Enein F, Brueck W, Lucchinetti C, Rodriguez M, Schmidbauer M, Jellinger K, Lassmann H (2004) Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol 14:43-50.
22. Hovelmeyer N, Hao Z, Kranidioti K, Kassiotis G, Buch T, Frommer F, von Hoch L, Kramer D, Minichiello L, Kollias G, Lassmann H, Waisman A (2005) Apoptosis of oligodendrocytes via Fas and TNF-R1 is a key event in the induction of experimental autoimmune encephalomyelitis. J Immunol 175:5875-5884.
23. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J (2001) A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 194:669-676.
24. Kassmann CM, Lappe-Siefke C, Baes M, Brugger B, Mildner A, Werner HB, Natt O, Michaelis T, Prinz M, Frahm J, Nave KA (2007) Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet 39:969-976.
25. Krishnamoorthy G, Saxena A, Mars LT, Domingues HS, Mentele R, Ben-Nun A, Lassmann H, Dornmair K, Kurschus FC, Liblau RS, Wekerle H (2009) Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat Med 15:626-632.
26. Lassmann H, Brunner C, Bradl M, Linington C (1988) Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyeli-nated lesions. ActaNeuropathol 75:566-576.
27. Lin R, Hiscott J (1999) A role for casein kinase II phosphorylation in the regulation of IRF-1 transcriptional activity. Mol Cell Biochem 191:169-180.
28. Lin W, Kemper A, Dupree JL, Harding HP, Ron D, Popko B (2006) Interferon-gamma inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. Brain 129:1306-1318.
29. Linker RA, Mauer M, Gaupp S, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka KV, Sendtner M, Gold R (2002) CNTF is a major protective factor in demyelinating CNS disease: a neuroprotective cytokine as modulator in neuroinflammation. Nat Med 8:620-624.
30. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707-717.
31. Martino G, Franklin RJ, Van Evercooren AB, Kerr DA, Stem Cells in Multiple Sclerosis (STEMS) Consensus Group (2010) Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat Rev Neurol 6:247-255.
32. Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, Kawakami T, Watanabe N, Kundig TM, Amakawa R, Kishihara K, Wakeham A (1993) Targeted disruption of IRF-1 or IRF-2 results in abnormal type IIFN gene induction and aberrant lymphocyte development. Cell 75:83-97.
33. Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, Yuan Q, Wong WM, Wang L, Su H, Chu TH, Guo J, Zhang W, So KF, Pepinsky B, Shao Z, Graff C, Garber E, Jung V, Wu EX, Wu W (2007) LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 13:1228-1233.
34. Ming X, Li W, Maeda Y, Blumberg B, Raval S, Cook SD, Dowling PC (2002) Caspase 1 expression in multiple sclerosis plaques and cultured glial cells. J Neurol Sci 197:9-18.
35. Ramana CV, Gil MP, Schreiber RD, Stark GR (2002) (2002) STAT1-dependent and independent pathways in IFN-y-dependent signaling. Trends Immunol 23:96-101.
36. Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R (2010) Central nervous system expression of interferon regulatory factor 1 regulates experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol 5:260-265.
37. Ren Z, Wang Y, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R (2011) IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination. J Neuroimmunol 233:147-159.
38. Ruulus SR, Bauer J, Sontrop K, Huitinga K, Hart BA, Dijkstra CD (1995) Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 56:207-217.
39. Smith KJ, McDonald WI (1999) The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 354:1649-1673.
40. Steinman L, Zamvil SS (2006) How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 60:12-21.
41. Swanborg RH (1988) Experimental allergic encephalomyelitis. Methods Enzymol 162:413-421.
42. Tada Y, Ho A, Matsuyama T, Mak TW (1997) Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking inter-feron regulatory factor-1. J Exp Med 185:231-238.
43. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N (2001) Family of transcription factors as regulators of host defense. Annu Rev Immunol 19:623-655.
44. Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, Marusic S (2007) IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol 178:2589-2598.
45. Tompkins SM, Padilla J, Dal Canto MC, Ting JP, Van Kaer L, Miller SD (2002) De novo CNS processing of myelin antigen is required for the initiation of EAE. J Immunol 168:4173-4183.
46. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Ax-onal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285.
47. Trebst C, Heine S, Lienenklaus S, Lindner M, Baumgartner W, Weiss S, Stangel M (2007) Lack of interferon-beta leads to accelerated remyeli-nation in a toxic model of central nervous system demyelination. Acta Neuropathol 114:587-596.
48. Wang Y, Ren Z, Tao D, Tilwalli S, Goswami R, Balabanov R (2010) STAT1/ IRF-1 signaling pathway mediates the injurious effect of interferon-gamma on oligodendrocyte progenitor cells. Glia 58:195-208.
49. Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, Decker C, Charifson P, Weber P, Germann UA, Kuida K, Randle JC (2007) (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther 321:509-516.
50. Waxman SG (2001) Acquired channelopathies in nerve injury and MS. Neurology 56:1621-1627.